Counts TLR3-PE 100 80 60 40 20 0 Counts TLR8-PE 100 80 60 40 20 0 Counts TLR9-PE 100 80 60 40 20 0 C AB Supplemental Figure 1.

Slides:

Advertisements

Similar presentations

Supplemental Figure 1 A No. at risk T T T

Advertisements

Supplemental Fig 1 Rt. Lung Tumor A B Murine lung cancer model. LLC were implanted as described in Fig 1. A) Representative histology showing the distribution.

Supplemental Table 1 Source and authentication of cell lines.

Supplemental Digital Content Figure 1A A Academic/Research Program Extent of Lung Resection No. of SubjectEventCensored Median Survival (95% CI)60 mo Survival.

Supplemental Figure 1. Loss of Stat3 expression did not change IFN-induced chemokine levels in tumors. (A) Realtime PCR analysis of mRNA expression levels.

Supplementary Figures NormalCRC CRC+5FU CRC+CPT11 100µm S1.

Supplementary Figure 1: Correlation analysis of DKC1 mRNA and dyskerin protein quantity in neuroblastoma cell lines.

Shimura Supplemental Figure 1

Reduced Level of CD44 and Hyaluronan Associated with Unfavorable Prognosis in Clinical Stage I Cutaneous Melanoma Jari M. Karjalainen, Raija H. Tammi,

Differences in the Expression Profiles of Excision Repair Crosscomplementation Group 1, X-Ray Repair Crosscomplementation Group 1, and βIII-Tubulin Between.

Lung squamous cell carcinoma

Volume 110, Issue 6, Pages (December 1996)

Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations

Foxp3+ Regulatory T Cells and Natural Killer Cells Distinctly Infiltrate Primary Tumors and Draining Lymph Nodes in Pulmonary Adenocarcinoma Thomas Schneider,

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Volume 131, Issue 4, Pages (April 2007)

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

Baseline tumor biopsies

The beauty of TLR agonists for CTCL

Skin-draining lymph nodes contain dermis-derived CD103− dendritic cells that constitutively produce retinoic acid and induce Foxp3+ regulatory T cells.

Cancer Immunotherapy by Dendritic Cells

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

Pleural Effusions from Patients with Mesothelioma Induce Recruitment of Monocytes and Their Differentiation into M2 Macrophages Anne-Laure Chéné, MD,

Volume 81, Issue 9, Pages (May 2012)

Tumor Necrosis as a Prognostic Factor for Stage IA Non-Small Cell Lung Cancer Seong Yong Park, MD, Hyun-Sung Lee, MD, PhD, Hee-Jin Jang, MD, Geon Kook.

Which patients should be operated on after induction chemotherapy for N2 non–small cell lung cancer? Analysis of a 7-year experience in 175 patients

Laurence Zitvogel, Guido Kroemer Cancer Cell

Days after cell inoculation Days after cell inoculation

Days after cell inoculation Days after cell inoculation

Differences in the Expression Profiles of Excision Repair Crosscomplementation Group 1, X-Ray Repair Crosscomplementation Group 1, and βIII-Tubulin Between.

Foxp3+ Regulatory T Cells and Natural Killer Cells Distinctly Infiltrate Primary Tumors and Draining Lymph Nodes in Pulmonary Adenocarcinoma Thomas Schneider,

IL-23 from Langerhans Cells Is Required for the Development of Imiquimod-Induced Psoriasis-Like Dermatitis by Induction of IL-17A-Producing γδ T Cells

IL-6 is dispensable for the suppressive activity of MDSC on primary CD4+ T-cell activation. IL-6 is dispensable for the suppressive activity of MDSC on.

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

ERCC1 and BRAC1 mRNA Expression Levels in the Primary Tumor Could Predict the Effectiveness of the Second-Line Cisplatin-Based Chemotherapy in Pretreated.

Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430 Thomas E.

Adjuvant Chemotherapy Is Associated With Improved Survival in Locally Invasive Node Negative Non-Small Cell Lung Cancer Usman Ahmad, MD, Traves D. Crabtree,

Toll-Like Receptor 3 Increases Allergic and Irritant Contact Dermatitis Naomi Nakamura, Risa Tamagawa-Mineoka, Mayumi Ueta, Shigeru Kinoshita, Norito.

Prognostic Factors in Patients with Pathologic T1-2N1M0 Disease in Non-small Cell Carcinoma of the Lung Katsunari Matsuoka, MD, Shinichi Sumitomo, MD,

Tregs and APC subsets in TDLNs of patients with cervical cancer.

Interstitial tumor-associated macrophages combined with tumor-derived colony- stimulating factor-1 and interleukin-6, a novel prognostic biomarker in non–small.

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Superior Suppressive Capacity of Skin Tregs Compared with Lung Tregs in a Model of Epicutaneous Priming Subhashree Mahapatra, Melanie Albrecht, Abdul.

Docetaxel Consolidation Therapy Following Cisplatin, Vinorelbine, and Concurrent Thoracic Radiotherapy in Patients with Unresectable Stage III Non-small.

Leora Horn, MD, MSc, FRCPC, Alan B. Sandler, MD, Joe B

Segmentectomy for selected cT1N0M0 non–small cell lung cancer: A prospective study at a single institute Hiroaki Nomori, PhD, Takeshi Mori, PhD, Koei.

Volume 130, Issue 1, Pages (July 2013)

Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small.

Re-evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non–Small-Cell Lung Cancer Using the National Cancer Database

Short-course induction chemoradiotherapy with paclitaxel for stage III non-small-cell lung cancer Thomas W Rice, MD, David J Adelstein, MD, Jay P Ciezki,

Volume 5, Issue 3, Pages (September 1996)

Dose-per-Fraction Escalation of Accelerated Hypofractionated Three-Dimensional Conformal Radiotherapy in Locally Advanced Non-small Cell Lung Cancer

CXCR5 expression accelerates Eμ-Tcl1 leukemogenesis and is indispensable for tumor cell recruitment to lymphoid B-cell follicles. CXCR5 expression accelerates.

Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations

Volume 29, Issue 5, Pages (November 2008)

Impact of HER2 Gene and Protein Status on the Treatment Outcome of Cisplatin-Based Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer

Clinical Relevance of Our Multimodality Prognostic Score

Volume 30, Issue 2, Pages (February 2009)

Supplementary Table 1. Summary of surface marker expression of adherent (A) and sphere-forming MRT cell lines (B), and primary tumors (C). A Sample CD146.

Adjuvant Chemotherapy for Non-small Cell Lung Cancer: Practice Patterns and Outcomes in the General Population of Ontario, Canada Christopher M. Booth,

Supplementary Figure S1

James D Luketich, Michael E Burt The Annals of Thoracic Surgery

Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural.

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Tumor-resident CD8+ T cells rapidly expand after IL-15/IL-15Rα complex treatment. Tumor-resident CD8+ T cells rapidly expand after IL-15/IL-15Rα complex.

A Randomized Phase II Trial Assessing in Advanced Non-small Cell Lung Cancer Patients with Stable Disease after Two Courses of Cisplatin-Gemcitabine an.

Cell counts of immune infiltrate and expression of galectin-1 and galectin-3 in the short-, medium-, and long-term survival cohorts. Cell counts of immune.

Presentation transcript:

Counts TLR3-PE Counts TLR8-PE Counts TLR9-PE C AB Supplemental Figure 1

A TLR7-PE No. of living cells (in million) B PBS CL264 Cisplatin CL264+ Cisplatin Percentage (apoptotic cells) PBS CL264 Cisplatin CL264+ Cisplatin Counts ** *** Supplemental Figure 2

PBS CL264 Cisplatin(100µM)Cisplatin(200µM) Cisplatin(300µM) CL264+Cisplatin(100µM)CL264+Cisplatin(200µM) CL264+Cisplatin(300µM) ns Tumor volume (mm 3 ) ** Supplemental Figure 3

A B Tumor volume (mm 3 ) day CL264 Cisplatin IRS661 ODN Supplemental Figure 4

PBS CL264 %CD3+ cells among CD45+ cells ns PBS CL nb CD3+ cells (x10 6 ) ns PBS CL264 %CD3+ CD4+ cells among CD45+ cells ns PBS CL264 nb CD3+ CD4+ cells (x10 6 ) ns CD3 + T cellsCD4 + T cells PBS CL %CD3+ CD8+ cells among CD45+ cells ns PBS CL264 nb CD3+ CD8+ cells (x10 6 ) ns CD8 + T cells PBS CL %CD3+ Foxp3+ cells among CD45+ cells ns nb CD3+ Foxp3+ cells (x10 6 ) PBS CL ns CD3 + Foxp3 + T Reg cells PBS CL %Gr1- CD11c+ cells among CD45+ cells nb Gr1- CD11c+ cells (x10 6 ) PBS CL264 Gr1 - CD11c + dendritic cells PBS CL264 %Gr1- CD11b+ cells among CD45+ cells PBS CL nb Gr1- CD11b+ cells (x10 6 ) Gr1 - CD11b + macrophages PBS CL %Gr1+ CD11b+ cells among CD45+ cells 0 PBS CL nb Gr1+ CD11b+ cells (x10 6 ) Gr1 + CD11b + MDSCs A B CD EF G ** Supplemental Figure 5

P value Percentage of TLR7 expressing tumor cells Supplemental Figure 6

P value Percentage of TLR7 expressing tumor cells Supplemental Figure 7

Overall Survival (OS) Time (months) Responders =55/166 Non-responders =111/166 P = Supplemental Figure 8

R 2 = p= % TLR7 in tumor cells in LN after chemotherapy % TLR7 in tumor cells in lung after chemotherapy Supplemental Figure 9

No Yes % TLR7 positive tumoral cells Tumor Downstaging A B Yes No Lymph Node Downstaging % TLR7 positive tumoral cells PatientsMean %TLR7 expressing cells P value for the mean Median %TLR7 expressing cells P value for the median Tumor downstaging Yes No4750 Lymph Node downstaging Yes No51 50 C Supplemental Figure 10